China National Accord Medicines 国药一致
2 significant filings since 30 May 2026: 1 on earnings pre-announcement and 1 on dividend. The latest, on 18 Aug 2026: 2026年半年度业绩快报.
自 30 May 2026 起有 2 份重大公告：earnings pre-announcement 1 份、dividend 1 份。最新一份（18 Aug 2026）：2026年半年度业绩快报。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 1 Sep 2023 | 西南证券 | 杜向阳 | Outperform 增持 | ▲ | Buy 买入 |
| 16 Mar 2021 | 群益证券 | 王睿哲 | Buy 买入 | ▼ | Outperform 增持 |
| 27 Apr 2020 | 西南证券 | 朱国广,杜向阳 | Buy 买入 | ▼ | Outperform 增持 |
| 29 Oct 2019 | 辉立证券 | 段炼 | Outperform 增持 | ▲ | Buy 买入 |
| 3 Sep 2019 | 辉立证券 | 段炼 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 信达证券 | 唐爱金,章钟涛 | Buy 买入 | 15 Apr 2026 | 1 | — |
| 西南证券 | 杜向阳 | Unrated | 8 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 2 reports. 每行为该券商近十二个月的最新研报；2 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。